Gilead Sciences (NASDAQ:GILD – Get Free Report) had its target price raised by stock analysts at TD Cowen from $125.00 to $145.00 in a research note issued on Thursday,MarketScreener reports. TD Cowen’s price target would indicate a potential upside of 3.91% from the stock’s current price. Get Gilead Sciences alerts:Check Out Our Latest Research Report on Gilead SciencesGilead Sciences Trading Down 0.1%Shares of Gilead Sciences stock opened at $139.55 on Thursday. Gilead Sciences News RoundupHere are the key news stories impacting Gilead Sciences this week:Positive Sentiment: Trodelvy received a boost after being added to NCCN treatment guidelines, improving adoption and commercial prospects for Gilead’s oncology franchise. Recommended StoriesReceive News & Ratings for Gilead Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences and related companies with MarketBeat.com's FREE daily email newsletter.